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The early detection of lung cancer can reduce the mortality. However, there is no effective means in clinical
settings for noninvasively detecting lung cancer. We previously developed 3 sputum miRNA biomarkers and 2
sputum small nucleolar RNA (snoRNA) biomarkers that can potentially be used for noninvasively diagnosing
lung cancer. Here we evaluate the individual and combined applications of the two types of biomarkers in
different sets of lung cancer patients and controls. Combined analysis of the miRNAs and snoRNAs has a
synergistic effect with 89 % sensitivity and 89 % specificity, and may provide a useful tool for lung cancer
early detection.Background
Non-small cell lung cancer (NSCLC), primarily caused
by cigarette smoking, is the leading cause of cancer-
related mortalities [1]. There are two major types of
NSCLC: adenocarcinoma (AC) and squamous cell car-
cinoma (SCC). The early detection of NSCLC may
decrease the mortality [1, 2]. However, there is no ef-
fective and noninvasive means for the early detection
[3]. Sputum is a noninvasively and easily accessible
body fluid that contains exfoliated bronchial epithelial
cells [4]. Molecular study of sputum could detect the
molecular abnormalities in the bronchial airways that
reflect those existing in primary lung tumors, and
thus provides a noninvasive approach for NSCLC
detection [5].
Small non-coding RNAs (ncRNAs) mainly consist of
microRNAs (miRNAs) and small nucleolar RNAs
(snoRNAs), and play an important role in the patho-
genesis of various cancers [6–16]. There is significant
interest in the development of the tumor-related
ncRNAs as biomarkers for cancer diagnosis [17]. We
have identified a panel of three sputum miRNA bio-
markers (miRs-21, 31, and 210) with 82.9 % sensitiv-
ity and 87.8 % specificity and a panel of two snoRNA
sputum biomarkers (snoRDs-66 and 78) with 74.6 %
sensitivity and 83.6 % specificity for lung cancer early* Correspondence: fjiang@som.umaryland.edu
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neous disease featuring field defects in the airway of
smokers [21, 22], a single biomarker type can’t
achieve the sensitivity and specificity required for
clinically diagnosing NSCLC. Because miRNAs and
snoRNAs have highly and actively different roles in
tumorigenesis, integrating the miRNA and snoRNA-
based biomarkers may improve the performance of
the biomarkers for NSCLC detection. Here we evalu-
ate the individual and combined applications of the
two different types of ncRNAs for the early detection
of lung cancer.
Findings
With a protocol approved by Institutional Review
Board of the University of Maryland Medical Center
Center, we collected sputum from 316 NSCLC pa-
tients and 528 cancer-free smokers. Of the 316 lung
cancer patients, 103 were diagnosed with stage I
NSCLC. We used the 103 stage I NSCLC patients as
cases. From the cancer-free subjects, we randomly se-
lected 117 individuals as control cases. The 103 stage
I NSCLC cases and 117 cancer-free smokers were
randomly split into a training set (Table 1) and an in-
ternal testing set (Table 2).
We determined expressions of the five ncRNAs
(miRs-21, 31, and 210, and snoRDs-66 and 78) by
quantitative reverse transcriptase PCR (qRT-PCR) in
the sputum samples [18, 23–27]. The panel of three
miRNAs (miRs-21, 31, and 210) and panel of twoistributed under the terms of the Creative Commons Attribution 4.0 International
by/4.0/), which permits unrestricted use, distribution, and reproduction in any
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Table 1 Characteristics of lung cancer patients and cancer-free smokers of a training set
NSCLC cases (n = 46) Controls (n = 55) P-value






African American 16 19
Pack-years 44.79 (Range, 5–172) 43.45 (Range, 5–109) 0.38
FEV1/FVC 0.45–0.79 0.43–0.80 0.10
Nodule size (cm) 4.79 (Range, 95.25) 1.29 (Range, 56.76) <0.01
Stage, all are stage I
Histological type
Adenocarcinoma 25
Squamous cell carcinoma 21
Abbreviations: NSCLC non-small cell lung cancer
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ing characteristic (ROC) curve (AUC) value of 0.90
and 0.86, respectively (Fig. 1). Interestingly, combined
use of the five ncRNAs produced 0.94 AUC (Fig. 1),
being significantly higher than that of the panel of
three miRNAs (0.90) or the panel of two snoRNAs
(0.86) (p < 0.05). Furthermore, combined analysis of
the five ncRNAs had higher sensitivity (89.13 % vs.
82.61 % or 73.91 %) and specificity (89.09 % vs.
85.45 % or 83.64 %) compared with the individual
panels (All P < 0.05). The expression level of the five
ncRNAs was associated with smoking history and sizeTable 2 Characteristics of lung cancer patients and cancer-free smo
NSCLC cases (n = 57)







Pack-years 43.89 (Range, 5–170)
FEV1/FVC 0.46–0.78
Nodule size (cm) 4.89 (Range, 96.22)
Stage, all are stage I
Histological type
Adenocarcinoma 31
Squamous cell carcinoma 26
Abbreviations: NSCLC non-small cell lung cancerof PN of participants (All P < 0.05). The expression
level of sputum miR-21 was more closely related with
AC (P < 0.05), whereas miR-210 was associated with
SCC (P < 0.05). However, overall, the panel of the five
ncRNA biomarkers didn’t exhibit special association
with a histological type of the NSCLC cases, and the
age, gender, ethnicity, and forced expiratory volume 1
(FEV1)/forced vital capacity (FVC) of the participants
(All P > 0.05). The validation of the ncRNA bio-
markers in a testing cohort confirmed that combined
study of miRNAs and snoRNAs in sputum had a syn-
ergistic effect for the early detection of NSCLC.kers of a testing set
Controls (n = 62) P-value







42.64 (Range, 5–112) 0.39
0.44–0.79 0.09
1.54 (Range, 54.89) <0.01
Fig. 1 Combined analysis of miRNAs and snoRNAs in sputum has a synergistic effect for lung cancer detection. a ROC curve of a panel of three
sputum miRNA biomarkers (miRs-21, 31, and 210) shows an AUC of 0.90 for differentiating NSCLC patients from the cancer-free subjects in terms
of sensitivity and specificity. b a panel of two snoRNA sputum biomarkers (snoRDs-66 and 78) creates an AUC of 0.86 for distinguishing NSCLC
patients from the cancer-free subjects. c combined study of the three miRNAs and two snoRNAs in sputum yields 0.94 AUC, which is significantly
higher than that of any single type of ncRNAs used alone (P < 0.05) for lung cancer detection
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Combined study of the miRNAs and snoRNAs has higher
sensitivity and specificity compared with a single type of
the ncRNA biomarkers, providing a noninvasive approach
for lung cancer early detection. Nevertheless, a prospective
project is required for validating the utility.Ethical statements
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